

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>C07D 473/16, A61K 31/52</b>		A1	(11) International Publication Number: <b>WO 98/52949</b> (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number:	PCT/EP98/02835	(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date:	14 May 1998 (14.05.98)		
(30) Priority Data:	9709945.1 17 May 1997 (17.05.97) GB		
(71) Applicant (for all designated States except US):	GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		
(72) Inventors; and			Published
(75) Inventors/Applicants (for US only):	BRODIE, Alastair, Couper [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). JONES, Martin, Francis [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). SEAGER, John, Frederick [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). WALLIS, Christopher, John [GB/GB]; Glaxo Wellcome plc, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB).		With international search report.
(74) Agent:	PIKE, Christopher, G.; Glaxo Wellcome plc, Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).		

(54) Title: CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS

(57) Abstract

There is described the hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate thereof. Also described are preparative routes and starting compounds for making the hemisulfate salt. The hemisulfate salt is useful in medicine, particularly in the treatment of viral infections.

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

## CARBOCYCLIC NUCLEOSIDE HEMISULFATE AND ITS USE IN TREATING VIRAL INFECTIONS

The present invention relates to a novel salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate thereof, pharmaceutical formulations containing such a compound and their use in medicine, specifically in the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection.

(1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol ('the compound') and its antiviral use, especially against HIV infections, is described in European patent Specification Number 0434450 which also refers to pharmaceutically acceptable derivatives specifically salts, esters and salts of such esters of the compound, and in particular describes hydrochloride salts of the compound. In addition PCT Patent Application No. PCT GB95/02014 describes the succinate salt of the above compound.

The compound (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol is currently under clinical investigation as an anti-HIV pharmaceutical agent. There exists a need for the compound to be prepared in a form suitable for ease of isolation in large scale manufacture, and for ease of formulating into an acceptable product for administration to humans. We have found that manufacture of the free base of the compound produces an amorphous solid which traps solvents and is, therefore, unsuitable for large scale purification, or for formulation, without additional purification procedures.

Whereas the succinate salt described in PCT Patent Application No. PCT/GB95/02014 has advantages in its preparation, for example, it forms the salt easily from stoichiometric ratios of the acid and base and crystallises very easily out of solution, it is not an ideal subject for pharmaceutical formulation,

specifically tableting. In particular, the succinate salt of the compound agglomerates to form a 'lumpy' mass which will not easily pour and is thus unsuitable for use in commercial tableting machines, such that an extra processing step of high energy milling is required to give a uniform particle size.

5 An additional complication attendant upon formulation of the succinate salt of the compound is that it can exist in several crystal forms, each form having slightly different physical properties. The preparation of the succinate salt of the compound requires close attention to avoid the preparation of undesired forms, which if formed require reworking to the desired form.

10

We have found that the advantages of the hemisulfate salt of the compound over the disclosed hydrochloride salts and succinate salt renders the hemisulfate salt particularly suitable and advantageous to prepare on a large scale, and in particular for use in the preparation of pharmaceutical formulations. Specifically

15 the hemisulfate salt forms a free flowing powder, which lacks any undue tendency to agglomerate, and which is easily poured and compacted, and thus ideal for use in commercial tableting machines without the need for milling. The salt is believed to exist as a single morphic and crystalline form. The salt does not readily hydrate or solvate (e.g. on storage). The salt filters and dries readily,

20 thereby assisting ease of preparation. A further advantage is the higher aqueous solubility of the hemisulfate as compared to the succinate, which makes the hemisulfate particularly suitable for the preparation of liquid formulations.

25 We have also found that where the hemisulfate salt is prepared by a 'salt exchange' process, that is to say by conversion of a precursor salt of (1S,4R)-*cis*-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, particularly the glutarate or succinate salt, an enrichment in optical purity over that of the precursor salt is achievable. Thus, the need for any further preparative or

purification steps to enhance the optical purity of the hemisulfate salt product may be reduced or eliminated.

According to the first aspect of the invention there is provided the hemisulfate salt  
5 of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate thereof, including a hydrate thereof, hereinafter referred to as the compound according to the invention.

For the avoidance of doubt, as used herein, the hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol means the salt formed between (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and sulfuric acid in a stoichiometric ratio of 2:1.

Further aspects of the invention include:

15 a) The compound of the invention for use in medicine, particularly in the treatment of viral infections, specifically an HIV or an HBV infection.

20 b) A method for the treatment of a viral infection particularly an HIV or an HBV infection in a human which comprises administering to said human an effective amount of the compound according to the invention.

25 c) Use of a compound according to the invention in the manufacture of a medicament for the treatment of a viral infection particularly an HIV or an HBV infection.

The compound of the invention is particularly useful for the treatment of HIV infections.

It will be appreciated by those skilled in the art that reference herein to treatment extends to prophylaxis as well as the treatment of established infections or symptoms.

5 Examples of clinical conditions caused by HIV infections which may be treated in accordance with the invention include Acquired Immune Deficiency Syndrome (AIDS) or symptoms that frequently precede AIDS, or related clinical conditions such as AIDS-related complex (ARC), progressive generalised lymphadenopathy (PGL), Kaposi's sarcoma, thrombocytopenic purpura, AIDS related neurological 10 conditions, such as multiple sclerosis or tropical paraparesis and also anti-HIV antibody-positive and HIV-positive conditions including AIDS asymptomatic patients.

15 The compounds of the invention may be administered alone or in combination with other therapeutic agents suitable in the treatment of HIV infections, such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs) for example zidovudine, zalcitabine, lamivudine, didanosine, stavudine, 5-chloro-2',3'-dideoxy-3'-fluorouridine, adefovir and (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, lovaride, non-NRTIs for example nevirapine, delavirdine,  $\alpha$ -APA, 20 HBY-1293 and efavirenz HIV protease inhibitors for example saquinavir, indinavir, nelfinavir, ritonavir and VX-478, other anti-HIV agents for example soluble CD4, immune modulators for example interleukin II, erythropoietin, tucareol, and interferons for example  $\alpha$  -interferon. In addition the compound of the invention may be administered in combination with other therapeutic agents suitable in the 25 treatment of HBV infections for example lamivudine, (2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine, immune modulators, and interferons as described above. Such combinations may be administered together or sequentially providing that any duration between the administration of each therapeutic agent does not diminish their additive effect.

While it is possible for the compound of the invention to be administered as the raw chemical, it is preferable and advantageous to present the compound of the invention as a pharmaceutical formulation, and represents a further feature of the

5 invention. The pharmaceutical formulation comprises the compound of the invention together with one or more acceptable carrier(s) therefor and optionally other therapeutic agents. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipients thereof.

10

The compounds according to the invention may be administered by any route appropriate to the condition to be treated, suitable routes including oral, rectal, nasal, topical (including transdermal, buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, 15 intrathecal and epidural). It will be appreciated that the preferred route may vary with, for example, the condition of the recipient.

For each of the above-indicated utilities and indications the amount required of the individual active ingredient will depend upon a number of factors including the severity of the condition to be treated and the identity of the recipient and will 20 ultimately be at the discretion of the attendant physician. In general, however, for each of these utilities and indications, a suitable, effective dose will be in the range of 1 to 120 mg per kilogram body weight of recipient per day, preferably in the range of 3 to 90 mg per kilogram body weight per day and most preferably in the range of 5 to 60 mg per kilogram body weight per day such as 5 to 20 mg per 25 kilogram body weight per day. The dose may if desired be presented as two, three, four or more sub-doses administered at appropriate intervals throughout the day.

The formulations include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. The formulations may conveniently be presented in unit dosage form and may be

5 prepared by any of the methods well known in the art of pharmacy. Such methods include the step of bringing into association the active ingredient with the carrier which constitutes one or more accessory ingredients. In general the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and

10 then, if necessary, shaping the product.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous liquid or a non-aqueous liquid; or as an

15 oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be presented as a bolus, or paste or may be contained within liposomes.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in

20 a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface-active or dispersing agent. Moulded tablets may be made by

25 moulding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active

ingredient therein using, for example, hydroxypropylmethyl-cellulose in varying proportions to provide the desired release profile.

A capsule may be made by filling a loose or compressed powder or an appropriate filling machine, optionally with one or more additives. Examples of 5 suitable additives include binders such as povidone, gelatin, lubricants, inert diluents, disintegrants as for tablets. Capsules may also be formulated to contain pellets or discrete sub-units to provide slow or controlled release of the outline ingredient. This can be achieved by extruding and spheronising a wet mixture of the drug plus an extrusion acid (e.g. microcrystalline cellulose) plus a diluent such 10 as lactose. The spheroids thus produced can be coated with a semi-permeable membrane (e.g. ethyl cellulose, Eudragit WE30D) to produce sustained release properties.

For infections of the eye or other external tissues, e.g., mouth and skin, the 15 formulations are preferably applied as a topical ointment or cream containing the active ingredient in an amount of, for example, 0.075 to 20% w/w, preferably 0.2 to 15% w/w and most preferably 0.5 to 10% w/w. When formulated in an ointment, the active ingredients may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredients may be formulated in a cream with an oil-in-water cream base or as in a water in oil base.

20 If desired, the aqueous phase of the cream base may include, for example, at least 40-45% w/w of a polyhydric alcohol, i.e. an alcohol having two or more hydroxyl groups such as propylene glycol, butane-1,3-diol, mannitol, sorbitol, glycerol and polyethylene glycol and mixtures thereof. The topical formulations 25 may desirably include a compound which enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such dermal penetration enhancers include dimethylsulfoxide and related analogues.

The oily phase of the emulsions of this invention may be constituted from known ingredients in a known manner. While this phase may comprise merely an emulsifier (otherwise known as an emulgent), it desirably comprises a mixture of at least one emulsifier with a fat or an oil or with both a fat and an oil. Preferably,

5 a hydrophilic emulsifier is included together with a lipophilic emulsifier which acts as a stabiliser. It is also preferred to include both an oil and a fat. Together, the emulsifier(s) with or without stabiliser(s) make up the so-called emulsifying wax, and the wax together with the oil and/or fat make up the so-called emulsifying ointment base which forms the oily dispersed phase of the cream formulations.

10 Emulgents and emulsion stabilisers suitable for use in the formulation of the present invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol, glyceryl mono-stearate and sodium lauryl sulphate.

According to a first process (A), the compound of the invention may be prepared by admixture of sulfuric acid and (1S,4R)-cis-4[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in a stoichiometric ratio of approximately 1:2, preferably in solution, more preferably in an aqueous organic solvent, preferably at elevated temperature, more preferably at the reflux temperature of the chosen solvent system. Upon cooling, crystals of the compound of the invention form. Preferably crystallisation is effected by 'seeding' the solution with

15 a small quantity of the compound of the invention. Optional washing and recrystallisation may be used to improve the purity of the product.

According to an alternative process (B), the compound of the invention may be formed by admixture of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol monosulfate (1:1 salt) and (1S,4R)-cis-4-[2-amino-25 6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in a substantially 1:1 molar ratio in solution.

A particularly advantageous process (C) for preparing the compound of the invention comprises conversion of a salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol to the compound of the invention. Suitable salts for conversion include dicarboxylic acid salts such as

5 the succinate, glutarate, hemisuberate (i.e. salt formed from 2:1, base: suberic acid), adipate, fumarate, hemisubacetate (i.e. salt formed from 2:1, base: sebacic acid), and pimelate salts. Mixtures of dicarboxylic acid salts may be employed. Use of the succinate and glutarate salts is preferred. Preparation of the succinate salt is described in PCT Application No. PCT/GB95/02014. Other salts of (1S,4R)-

10 cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol useful for conversion to the hemisulfate include the benzoate and salicylate salts and mixtures thereof. Such salts represent a further feature of the invention.

In one preferred aspect of the present invention, the conversion may be effected by admixture of sulfuric acid and a salt of (1S,4R)-cis-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol other than the hemisulfate in the appropriate stoichiometric ratio. For the avoidance of doubt, the appropriate stoichiometric ratio (i.e. salt of (1S,4R)-cis-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol:sulfuric acid) will be 2:1 if the salt is a 1:1 salt (i.e. ratio of (1S,4R)-cis-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol to acid is 1:1) and 1:1 if the salt is a 2:1 salt (i.e. ratio of (1S,4R)-cis-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol to acid is 2:1). The admixing is preferably carried out in solution, more preferably in an aqueous organic solvent, preferably at elevated temperature, more preferably at the reflux temperature of

15 the chosen solvent system. The hemisulfate crystals are formed upon cooling of the reaction mixture, optionally with seeding, as previously described. This process of salt interconversion provides advantages in terms of the purity of the compound of the invention thereby obtained.

20

25

10

A particularly advantageous feature of the process of conversion of the abovementioned salts to the hemisulfate is that the conversion results in an enhancement of optical purity, i.e. there is a lesser amount of the unwanted (1R, 4S) isomer in the compound of the invention thus produced than there was in the 5 starting salt.

Suitable solvents for use in the processes of the invention include alcohols such as, for example, ethanol or propan-2-ol. Such solvents may be used alone or in admixture, optionally in the presence of a further organic solvent, such as acetone, or in the presence of water, thereby forming an aqueous organic solvent 10 mixture.

The compound (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol can be synthesised in accordance with European Patent Specification Number 0434450 or alternatively PCT Application No. PCT/GB/9500225 which are incorporated herein by reference.

15 The succinate salt of the compound (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclo-pentene-1-methanol can be synthesised in accordance with PCT Patent Application No. PCT/GB95/02014, which is incorporated herein by reference.

20 The invention is further described in the following examples which are illustrative thereof and not limiting thereto.

As used in the following examples, IMS means industrial methylated spirits (denatured ethanol) and IPA means propan-2-ol.

Intermediate 1**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol**

5 (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt (EP0434450 (80g)) was heated under reflux in industrial methylated spirits (800ml) with cyclopropylamine (110ml) for about 5 h. The mixture was cooled to 70 to 75°C and an aqueous solution of sodium hydroxide (10M, 55ml, 2 molar equivalents) was added dropwise. The resultant suspension  
10 was cooled to 20 to 25°C and filtered, the collected solids being washed with IMS (2x60ml). The combined filtrates and washings were treated with charcoal (8g) and the filter-aid Harborlite J2 (4g) then heated to 40 to 50°C. After about 0.5h, the mixture was cooled to 15 to 20°C and the solids were removed by filtration, washed with IMS (2x160ml and 1x80ml) and the combined filtrates and washings  
15 were concentrated by distillation under reduced pressure to a residual volume of about 240ml. IMS (560ml) was added and the mixture was concentrated under reduced pressure to a residual volume of about 240ml. The dilution and reconcentration was repeated and the resultant concentrate was diluted with IMS (240ml) and heated to obtain a complete solution which was divided into four  
20 equal portions.

One portion was concentrated by distillation under reduced pressure to a residual volume of about 60ml. Acetone (140ml) was added and the mixture re-concentrated to about 60ml. This dilution and re-concentration was repeated twice to give a fluid volume of about 80ml. The resultant suspension was cooled  
25 to 0 to 5°C and the product was filtered, washed with cold (0 to 5°C) acetone (2x40ml) and dried in vacuo to give the title compound as an orange solid (16.8g, 90%); <sup>1</sup>H-NMR (D<sub>2</sub>O)δ: 7.71(s, 1, purine CH), 6.22(m, 1, =CH), 5.93(m, 1, =CH), 5.37(m, 1, NCH), 3.61(m, 2, OCH<sub>2</sub>), 3.04(br m, 1, CH of cyclopropyl), 2.82(br m,

1,CH), 2.80-2.70(m, 1, CH), 1.58-1.50(m, 1, CH), 0.90-0.60(m, 4, 2 x CH<sub>2</sub> of cyclopropyl).

Example A

5

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt.**

A stirred mixture of water (25ml) and IPA (100ml) was heated to 45 to 55°C and 10 (1S, 4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol succinate salt (WO96/06844 (50g)) was added, and washed in with IPA (12.5ml). The mixture was heated under reflux for about 0.5h to give a clear solution and then cooled to 65 to 75°C and a solution of concentrated sulfuric acid (6.07g) in water (12.5ml) was added. A mixture of IPA (37.5ml) and water 15 (12.5ml) was added and the solution was cooled to 45 to 55°C, whereupon a seed of authentic (1S, 4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt was added. After stirring in this temperature range for about 1h to allow crystallisation to become established, further IPA (300ml) was added, maintaining the temperature of the mixture in the 20 range 45 to 55°C. The suspension was cooled to 0 to 5°C over about 2h, and the product was filtered, washed with IPA (2x75ml), and dried in vacuo at 40 to 45°C to give the title compound as a fawn coloured powder (34.3g, 90%); m.p. 224-225°C (decomp.); <sup>1</sup>H-NMR (DMSO-d6)δ: 10.76(br m, 1, purine NH), 8.53(vbr m, 1, NH), 7.80(s, 1, purine CH), 6.67(br m, 1, NH<sub>2</sub>), 6.13(m, 1, =CH), 5.87(m, 1, =CH), 25 5.40(m, 1, NCH), 3.45(d, J = 5.8Hz, 2, OCH<sub>2</sub>), 2.96(br m, 1, CH of cyclopropyl), 2.87(m, 1, CH), 2.67-2.57(m, 1, CH), 1.65-1.55(m, 1, CH), 0.84-0.64(m, 4, 2 x CH<sub>2</sub> of cyclopropyl).

Example B**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt.**

5 A stirred suspension of (1S,4R-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol succinate salt (WO96/06844 (1000g)) in industrial methylated spirit (IMS) (7000ml) was heated under reflux for about 0.5h to obtain a clear solution. The solution was cooled to about 70°C and a solution of concentrated sulfuric acid (121g) in IMS (1000ml) was added. After seeding with

10 authentic (1S,4R-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene -1-methanol hemisulfate salt, the mixture was stirred at about 70°C to allow the product to crystallise. After about 0.5h, the mixture was cooled to 20 to 30°C over about 2h. The mixture was filtered, the cake was washed with IMS (2x 2000ml) and dried in vacuo at 40 to 45°C to give the title compound as a fawn

15 coloured powder (764g, 92%), spectra identical to those of the product of Example A.

Example C

20 **Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt**

A suspension of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol succinate salt (10g) in industrial methylated spirit (IMS) (30ml) and water (5ml) was heated under reflux for about 0.5h to give a clear solution. The solution was cooled to 55 to 65°C and a solution of concentrated sulfuric acid (1.21g) in water (2.5ml) was added, followed by a mixture of IMS (7.5ml) and water (2.5ml). The solution was further cooled to 45 to 55°C and

acetone (80ml) was added over about 0.25h to the mixture within this temperature range. The resultant suspension was cooled to 0 to 5°C over about 1h. The product was filtered, washed with acetone (2x10ml) and dried in vacuo at 40 to 45°C to give the title compound as a fawn coloured powder (6.28g, 82%)  
5 which was spectroscopically identical to the product of Example A.

Example D

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt**

10 (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (Intermediate 1) (5.98g) was suspended in IMS (40ml) and the suspension was heated under reflux for about 0.5h. The mixture was cooled to 70 to 75°C and a mixture of a solution of concentrated sulfuric acid in IMS (10M, 1.03ml, 0.5 molar equivalent) and IMS (10ml) was added dropwise. The acid was  
15 washed in with further IMS (10ml) and the resultant suspension was cooled to 0 to 5°C. The product was isolated by filtration, washed with IMS (2 x 12ml) and dried in vacuo at 40 to 45°C to yield the title compound as a pale yellow solid (6.15g, 88%), spectra identical to those of the product of Example A.

Example E

20 **Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt**

A further portion of the IMS solution of Intermediate 1 was heated to 75 to 80°C to ensure complete solution. This was cooled to 70 to 75°C and a solution of  
25 concentrated sulfuric acid (3.90g) in IMS (30ml) was added dropwise, to give an orange coloured suspension. The mixture was cooled to 0 to 5°C over about 2h

and the product was filtered, washed with IMS (2x40ml) and dried in vacuo at 40 to 45°C to give the title compound as a yellow/orange solid (17.7g, 76%), spectra identical to those of the product of Example A.

Of this product, 5.0g was suspended in a mixture of isopropanol (IPA) (40ml) and 5 water (10ml) and heated under reflux for about 0.5h and then allowed to cool to 55 to 60°C, whereupon seeds of authentic (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt were added. The suspension was cooled further to 0 to 5°C and the temperature 10 was maintained for about 1h. The solid was filtered, washed with IPA (2x5ml) and dried in vacuo at 40 to 45°C to yield the title compound as a buff coloured 15 powder (4.4g, 88%), spectra identical to those of the product of Example A.

#### Example F

**(1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol benzoate salt**

15 (1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt EP0434450 (70g) was heated under reflux in IMS (700ml) with cyclopropylamine (94.5ml) for about 4h. The solution was cooled to 45 to 50°C and treated with filter-aid Harborlite J2 (3.5g) and charcoal (7g). After about 0.5h, 20 the mixture was cooled to 20 to 25°C and filtered. The solids were washed with IMS (2 x 140ml) and the combined filtrates and washings were concentrated by distillation under reduced pressure to a volume of about 210ml. After dilution with IMS, (490ml) the solution was re-concentrated to about 210ml. The dilution and reconcentration was repeated once and the final concentrate was divided into 25 seven equal portions.

One portion was diluted with IMS (80ml) and warmed until a complete solution was obtained. Benzoic acid (4.85g) was added as a single portion and the mixture was heated at 70 to 75°C to give a complete solution, which was then allowed to cool slowly. At 40 to 45°C the mixture was seeded with authentic

5 (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol benzoate salt and the mixture was further cooled to 0 to 5°C. The solid was filtered, washed with IMS (2x20ml) and dried in vacuo at 40 to 45°C to give the title compound as a white solid (8.7g, 64%), mpt: 156-157°C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) $\delta$ : 7.95(m, 2, benzoate CH), 7.63(m, 1, benzoate CH), 7.61(s, 1, purine CH), 7.50(m, 2, benzoate CH), 7.28(br m, 1, NH), 6.11(m, 1, =CH), 5.86(m, 1, =CH), 5.81(br m, 1, OH), 5.39(m, 1, NCH), 3.45(d, J = 6.0Hz, 2, OCH<sub>2</sub>), 3.04(br m, 1, CH of cyclopropyl), 2.87(br m, 1, CH), 2.65-2.55(m, 1, CH), 1.63-1.53(m, 1, CH), 0.70-0.54(m, 4, 2 x CH<sub>2</sub> of cyclopropyl).

10

15 Example G

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt.**

A suspension of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol benzoate salt (5g) in IPA (25ml) was warmed to 60 to 65°C. A solution of concentrated sulfuric acid (0.64g) in water (1.25ml) was added and the resultant cloudy suspension was warmed to 70 to 75°C. The mixture was cooled to 20 to 25°C and filtered. The solid was washed with IPA (2x10ml) and dried in vacuo at 40 to 45°C to give the title compound as a white solid (3.57g, 87%), spectra identical to those of the product of Example A.

20

25

Example H

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol glutarate salt.**

(1S,4R)-cis-4-[2-amino-6-chloro-9H-purin-9-yl]-2-cyclopentene-1-methanol hydrochloride salt (EP0434450) (25g) was heated under reflux in IMS (250ml) with cyclopropylamine (30ml) for about 4h. The solution was cooled to 45 to 50°C, diluted with IMS (75ml) and treated with charcoal (1g) and filter-aid Harborlite J2 (0.5g). After about 1h, the mixture was cooled to 20 to 25°C and filtered. The solids were washed with IMS (50ml) and the combined filtrates and washings were diluted with IMS (150ml) and then concentrated by distillation under reduced pressure to about 75ml. The mixture was diluted with IMS (90ml) and re-concentrated to about 75ml. The process of dilution and re-concentration was repeated twice more. The final concentrate was diluted with IMS (75ml) and heated to 70 to 75°C to give a solution. To this was added a solution of glutaric acid (13g) in IMS (75ml) which had been pre-heated to 70 to 75°C. The mixture was further diluted with IMS (25ml) and cooled to about 25°C over about 2 hours. The mixture was further cooled to 0 to 5°C, stirred for about 2 hours and filtered. The product was washed with IMS (2x50ml) and dried in vacuo at about 45°C to furnish the title compound as a light brown solid (27.1g, 78%); mp. 184-188°C; <sup>1</sup>H-NMR (DMSO-d<sub>6</sub>)δ: 7.60(s, 1, purine CH), 7.27(br m, 1, NH), 6.10(m, 1, =CH), 5.86(m, 1, =CH), 5.82(br m, 1, OH), 5.39(m, 1, NCH), 3.44(d, J = 5.9Hz, 2, OCH<sub>2</sub>), 3.04(br m, 1, CH of cyclopropyl), 2.87(br m, 1, CH), 2.65-2.55(m, 1, CH), 2.24(t, J = 7.2Hz, 4, glutarate 2 x CH<sub>2</sub>), 1.70(m, J = 7.2Hz, 2, glutarate CH<sub>2</sub>), 1.62-1.54(m, 1, CH), 0.68-0.54(m, 4, 2 x CH<sub>2</sub> of cyclopropyl).

25 Example I

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt.**

A suspension of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol glutarate salt (20g) in a mixture of IPA (80ml) and water (20ml) was heated to reflux to give a solution. The solution was cooled to about 75°C and a solution of concentrated sulfuric acid (2.4g) in water (5ml) was added.

5 The resultant solution was diluted with a mixture of IPA (16ml) and water (4ml) and then with IPA (20ml). The solution was cooled to 50 to 55°C, seeded with authentic (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt and stirred for about 30 minutes. To the resultant suspension was added IPA (160ml) over about 15 minutes then the 10 suspension was cooled to about 25° C over about 2 hours and then to about 0 - 5° C . After stirring for a further 2 hours the product was filtered, washed with IPA (2x40ml) and dried in vacuo at about 45°C to give the title compound as a light brown solid (14.98g, 93%), spectra identical to those of the product of Example A.

15 Example J

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt from the succinate salt in the presence of its enantiomer.**

20 A mixture of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, succinate salt and its enantiomer (134g) having an enantiomeric ratio of 97.5:2.5 as shown by chiral HPLC (eluant (1.0 v/v acetonitrile in aqueous 0.05M potassium phosphate buffer, pH 6.5; column ChromTech Chiral-AGP, 100 x 4.0mm; flow 1.0ml/min; detection at 220nm) was 25 suspended in isopropanol (IPA) (302ml) and water (67ml) and heated to reflux to give a clear solution. The solution was cooled to 75 to 80°C and a solution of concentrated sulfuric acid (16.26g) in water (33.5ml) was added, and the solution

was clarified by a hot filtration, following through the filter with a mixture of IPA and water (3:1, 134ml). The filtrates and washings were cooled to 45 to 50°C and seeded with authentic(1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, hemisulfate salt. Further IPA (804ml) was added in 5 this temperature range and the resultant suspension was cooled to 0 to 5°C. The suspension was filtered and the product was washed with IPA (2x200ml) and dried in vacuo at 40 to 45°C to give the title compound as a white crystalline solid (75g, 68%).

10 Analysis of the product by chiral HPLC (conditions as above) showed the ratio of enantiomers to be 99.2:0.8.

A range of similar experiments was carried out on 8g scale using different ratios of enantiomers of the input succinate salt with the same experimental protocol. The results are summarised below in tabular form:

RATIO OF ENANTIOMERS OF INPUT SUCCINATE SALT	RATIO OF ENANTIOMERS OF PRODUCT HEMISULFATE SALT
99.5 : 0.5	99.9 : 0.1
99.0 : 1.0	99.7 : 0.3
98.0 : 2.0	99.5 : 0.5
96.0 : 4.0	99.0 : 1.0

#### Example K

**Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt from the glutarate salt in the presence of its enantiomer.**

A mixture of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, glutarate salt and its enantiomer (100g) having an enantiomeric ratio of 98.6:1.4 as shown by chiral HPLC (conditions as above in

5 Example J) was suspended in isopropanol (IPA) (400ml) and water (100ml) and heated to reflux to give a clear solution. The solution was cooled to 70 to 75°C and a solution of concentrated sulfuric acid (12.01g) in water (25ml) was added, followed by a mixture of IPA and water (4:1, 100ml) and then by IPA (100ml). The solution was cooled to 50 to 55°C and seeded with authentic (1S,4R)-cis-4-

10 [2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, hemisulfate salt. Further IPA (800ml) was added in this temperature range and the resultant suspension was cooled to 0 to 5°C. The suspension was filtered and the product was washed with IPA (2x200ml) and dried in vacuo at 40 to 45°C to give the title compound as a white crystalline solid (72g, 90%).

15 Analysis of the product by chiral HPLC (conditions as above in Example J) showed the ratio of enantiomers to be 99.6:0.4.

#### Example L

20 **Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol salicylate salt.**

(1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (Intermediate 1) (1.0g) and salicylic acid (0.482g) were heated in IMS (about 25ml) until a clear solution was formed. This was allowed to cool to about 25 20° C and the resultant suspension was filtered and the solid product dried in vacuo at about 40° C to give the title compound as a white solid, (1.163g, 78%); m.pt: 195 - 198° C; <sup>1</sup>H-NMR (dmso-d<sub>6</sub>)δ: 7.78(d of d, J=7.7Hz, J= 1.7Hz, 1H, aromatic CH); 7.66(s, 1H, purine CH); 7.66(br m, 1H, NH); 7.43-7.48(m, 1H, aromatic CH); 6.85-6.92(m, 2H, 2 x aromatic CH); 6.11(m, 1H, =CH); 6.11(br m, 30 1H, OH); 5.87(m, 1H, =CH); 5.40(m, 1H, NCH); 3.45(m, 2H, OCH<sub>2</sub>); 3.03(br m,

1H, CH of cyclopropyl); 2.87(m, 1H, CH); 2.55-2.65(m, 1H, CH); 1.63-1.55(m, 1H, CH); 0.73-0.58(m, 4, 2xCH<sub>2</sub> of cyclopropyl).

The so-formed salicylate salt may be converted to the desired hemisulfate salt by 5 a method analogous to that described at Example G for conversion of the benzoate salt to the hemisulfate salt.

#### Example M

10 **Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol monosulfate salt.**

A stirred suspension of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (10.00g) in industrial methylated spirits (IMS) (40ml) was heated to 60°C to obtain a clear solution. A solution of concentrated 15 sulfuric acid (6.99g) in IMS (15ml) was added dropwise, and the mixture was heated under reflux for about 0.25h to once more obtain a clear solution. This mixture was cooled to 20 to 30°C over about an hour, with crystallisation occurring during the cooling. This suspension was further cooled to 0 to 5°C over about 0.25h, and stirred for about 1h within this temperature range. The product 20 was filtered, washed with IMS (2 x 15ml), and dried in vacuo at 40 to 45°C to give the title compound as a fine white powder (9.07g, 67.5%); <sup>1</sup>H-NMR (DMSO-d6)δ: 0.78 (2H, m), 0.93 (2H, m), 1.10 (3H, t, J 7.1Hz) (ethanol), 1.63 (1H, dt, J 13.8, 5.5Hz), 2.64 (1H, dt, J 13.8, 8.8Hz), 2.8 – 3.0 (3H broad m), 3.46 (2H, m), 3.74 (2H, q, J 7.1Hz) (ethanol), 5.42 (1H, m), 5.88 (1H, m), 6.17 (1H, m), 5.4 – 7.8 25 (broad, exchangeable), 8.0 (1H, s).

#### Example N

30 **Preparation of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol hemisulfate salt.**

A stirred suspension of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol monosulfate salt (5.00g), and (1S,4R)-cis-4-[2-

amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (3.725g) in isopropanol (IPA) (30ml) and water (10ml) was heated under reflux for about 0.25h to obtain a clear solution. The solution was cooled to about 50 to 55°C, and IPA (40ml) was added over about 0.25h maintaining the temperature at 50 to 5 55°C. Crystallisation occurred during the addition. The mixture was cooled to 20 to 30°C over about an hour, then further cooled to 0 to 5°C over about 0.25h, and stirred for about 1h within this temperature range. The product was filtered, washed with IPA (2 x 10ml), and dried in vacuo at 40 to 45°C to give the title compound as a fine white powder (5.17g, 59.1%), spectra identical to those of the 10 product of Example A.

Example 1: Tablet Formulations

The following formulations A, B and C are prepared by wet granulation of the ingredients with a solution of povidone, followed by addition of magnesium stearate and compression.

15 Formulation A

		<u>mg/tablet</u>	<u>mg/tablet</u>
	(a) Active ingredient	250	250
	(b) Lactose B.P.	210	26
	(c) Povidone B.P.	15	9
20	(d) Sodium Starch Glycollate	20	12
	(e) Magnesium Stearate	5	3
		500	300

Formulation B

		<u>mg/tablet</u>	<u>mg/tablet</u>
5	(a) Active ingredient	250	250
	(b) Lactose	150	-
	(c) Avicel PH 101	60	26
	(d) Povidone B.P.	15	9
	(e) Sodium Starch Glycollate	20	12
	(f) Magnesium Stearate	<u>5</u>	<u>3</u>
		500	300

10 Formulation C1 (Controlled Release Formulation)

The formulation is prepared by wet granulation of the ingredients (below) with a solution of povidone followed by the addition of magnesium stearate and compression.

		<u>mg/tablet</u>
15	(a) Active Ingredient	500
	(b) Hydroxypropylmethylcellulose (Methocel K4M Premium)	112
	(c) Lactose B.P.	53
	(d) Povidone B.P.C.	28
	(e) Magnesium Stearate	<u>7</u>
		700

Capsules are prepared by dispersing the active ingredient in the lecithin and arachis oil and filling the dispersion into soft, elastic gelatin capsules.

Formulation C (Controlled Release Capsule)

The following controlled release capsule formulation is prepared by extruding ingredients a, b, and c using an extruder, followed by spheronisation of the extrudate and drying. The dried pellets are then coated with release-controlling membrane (d) and filled into a two-piece, hard gelatin capsule.

		<u>mg/capsule</u>
5	(a) Active Ingredient	250
	(b) Microcrystalline Cellulose	125
	(c) Lactose BP	125
	(d) Ethyl Cellulose	<u>13</u>
10		513

Formulation D (film coated tablet)

The following film coated tablet is prepared using a direct compression process.

The hemisulfate salt of (1S,4R)-*cis*-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol is sifted and blended with microcrystalline

15 cellulose and sodium starch glycolate. Magnesium stearate and colloidal silicon dioxide are then sifted and blended with the other ingredients. The blend is compressed into tablets which are then coated using standard film coating technology.

		<u>mg/tablet</u>
20	<u>Tablet Core</u>	
	(a) hemisulfate salt	351.0
	(b) Microcrystalline Cellulose	414.6
	(c) Sodium Starch Glycolate	24.0
25	(d) Magnesium Stearate	<u>8.0</u>

25

(e)	Colloidal Silicon Dioxide	2.4
<b>Total Core Tablet Weight</b>		<b>800.0</b>

Tablet Coat

(f)	Opadry™ Yellow	24.0 (g)	
5	(g)	Purified Water USP	q.s.
<b>Total Tablet Weight</b>		<b>824.0</b>	

The amount of colloidal silicon dioxide present in the tablet core may be varied to e.g. 0.8mg.

Example 2: Injectable Formulation

10	Active ingredient	0.200 g	
	Sterile, pyrogen free phosphate buffer (pH 7.0)	to	10 ml

The active ingredient is dissolved in most of the phosphate buffer (35-40°C), then made up to volume and filtered through a sterile micropore filter into a sterile 10ml amber glass vial (type 1) and sealed with sterile closures and overseals.

Example E: Intramuscular Injection

Active Ingredient	0.20 g	
Benzyl Alcohol	0.10 g	
Glycofurool 75	1.45 g	
20 Water for Injection	q.s. to	3.00 ml

The active ingredient is dissolved in the glycofurool. The benzyl alcohol is then added and dissolved, and water added to 3 ml. The mixture is then filtered through a sterile micropore filter and sealed in sterile 3 ml glass vials (type 1).

Example 4:

5 Syrup Suspension

	Active ingredient	0.2500 g
	Sorbitol Solution	1.5000 g
	Glycerol	2.0000 g
	Dispersible Cellulose	0.0750 g
10	Sodium Benzoate	0.0050 g
	Flavour, Peach 17.42.3169	0.0125 ml
	Purified Water q.s. to	5.0000 ml

The sodium benzoate is dissolved in a portion of the purified water and the sorbitol solution added. The active ingredient is added and dispersed. In the 15 glycerol is dispersed the thickener (dispersible cellulose). The two dispersions are mixed and made up to the required volume with the purified water.

Example 5: Suppository

		<u>mg/suppository</u>
	Active Ingredient	250
20	Hard Fat, BP (Witepsol H15 - Dynamit Nobel)	<u>770</u>
		1020

The active ingredient is used as a powder wherein at least 90% of the particles are of 63 $\mu$ m diameter or less.

One-fifth of the Witepsol H15 is melted in a steam-jacketed pan at 45°C maximum. The active ingredient is sifted through a 200µm sieve and added to the molten base with mixing, using a silverson fitted with a cutting head, until a smooth dispersion is achieved. Maintaining the mixture at 45°C, the remaining

5 Witepsol H15 is added to the suspension and stirred to ensure a homogenous mix. The entire suspension is passed through a 250µm stainless steel screen and, with continuous stirring, is allowed to cool to 45°C. At a temperature of 38°C to 40°C 2.02g of the mixture is filled into suitable plastic moulds. The suppositories are allowed to cool to room temperature.

10 Example 6: Pessaries

	<u>mg/pessary</u>
Active ingredient	250
Anhydrous Dextrose	380
Potato Starch	363
15 Magnesium Stearate	7
	1000

The active ingredient is used as a powder wherein at least 90% of the particles are of 63µm diameter or less.

20 The above ingredients are mixed directly and pessaries prepared by direct compression of the resulting mixture.

Example 7: Topical formulation

	<u>Cream</u>
Active compound	5.00g
Glycerol	2.00g

Cetostearyl alcohol	6.75g
Sodium lauryl sulphate	0.75g
White soft paraffin	2.50g
Liquid paraffin	5.00g
5 Chlorocresol	0.10g
Purified water to	100.00g

Dissolve the active compound in a mixture of purified water and glycerol and heat to 70°C. Heat the remaining ingredients at 70°C. Add the two parts  
10 together and emulsify. Cool and fill into containers.

CLAIMS

1. The hemisulfate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol or a solvate thereof.
2. The compound as claimed in Claim 1 in the form of a hydrate.
- 5 3. A method for the treatment of a viral infection in a human host which comprises administering to said host an effective amount of a compound as claimed in Claim 1 or Claim 2.
4. A compound as claimed in Claim 1 or Claim 2 for use in medicine.
5. Use of a compound as claimed in Claim 1 or Claim 2 in the manufacture of a 10 medicament for the treatment of a viral infection.
6. Use of a compound as claimed in Claim 5 wherein said viral infection is an HIV or HBV infection.
7. A process for the preparation of the compound claimed in Claim 1 or Claim 2 which process comprises:  
15 admixture of sulfuric acid and (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in a stoichiometric ratio of approximately 1:2.
8. A process for the preparation of the compound claimed in Claim 1 or Claim 2 which process comprises:

admixture of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol sulfate (1:1 salt) and (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol in a substantially 1:1 molar ratio in solution.

- 5 9. A process for the preparation of the compound claimed in Claim 1 or Claim 2 which process comprises admixture of sulfuric acid and a salt of (1S,4R)-cis- 4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol other than the hemisulfate salt.
10. A process as claimed in Claim 9 wherein said sulfuric acid and said salt are present in approximately the stoichiometric ratio required to form the compound.
11. A process as claimed in either of Claims 9 or 10 wherein the salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol is a salt with a dicarboxylic acid.
15. A process as claimed in Claim 11 wherein said salt with a dicarboxylic acid is selected from the group consisting of succinate, glutarate, hemisuberate, adipate, fumarate, hemisebacate and pimelate salts and any mixtures thereof.
20. A process as claimed in either of Claims 9 or 10 wherein the salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol is selected from the group consisting of benzoate and salicylate salts and any mixtures thereof.
14. A process as claimed in any of Claims 9 to 13 wherein the optical purity of the hemisulfate is greater than that of the starting salt.

15. A pharmaceutical formulation comprising a compound as claimed in Claim 1 or Claim 2 and a pharmaceutically acceptable carrier therefor.
16. A pharmaceutical formulation as claimed in Claim 15 in the form of a tablet, a capsule, or liquid formulation.
- 5 17. A pharmaceutical formulation as claimed in Claim 15 adapted for parenteral administration.
18. A pharmaceutical formulation as claimed in any of Claims 15 to 17 additionally comprising one or more therapeutic agents selected from the group consisting of nucleoside reverse transcriptase inhibitors, non-nucleoside reverse 10 transcriptase inhibitors, protease inhibitors, immune modulators and interferons.
19. A dicarboxylate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol wherein said dicarboxylate is selected from the group consisting of glutarate, hemisuberate, adipate, fumarate, hemisebacate and pimelate.
- 15 20. The glutarate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol.
21. The monosulfate, benzoate or salicylate salt of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 98/02835

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 C07D473/16 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 434 450 A (THE WELLCOME FOUNDATION LIMITED) 26 June 1991 cited in the application see the whole document, particularly page 4, lines 45-50, and examples 29, 30 ---	1-21
A	WO 96 06844 A (THE WELLCOME FOUNDATION LIMITED) 7 March 1996 cited in the application see the whole document	1-21
P, X	WO 97 49410 A (GLAXO GROUP LIMITED) 31 December 1997 see the whole document, particularly page 5, line 13 -----	1-21



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
1 September 1998	09/09/1998
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Allard, M

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/02835

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: 3 because they relate to subject matter not required to be searched by this Authority, namely:  
**Remark:** Although claim 3 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking(Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

#### Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

## Information on patent family members

International Application No

PCT/EP 98/02835

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 434450	A 26-06-1991	AP 196	A	30-06-1992
		AU 633672	B	04-02-1993
		AU 6841990	A	27-06-1991
		CA 2033044	A	23-06-1991
		CN 1054981	A, B	02-10-1991
		CZ 9006583	A	12-11-1997
		FI 906367	A	23-06-1991
		FI 970666	A	17-02-1997
		IL 96748	A	31-07-1995
		MX 9203215	A	01-07-1992
		NZ 236593	A	26-01-1994
		PL 167097	B	31-07-1995
		PT 96321	A	30-09-1991
		RU 2068849	C	10-11-1996
		RU 2091386	C	27-09-1997
		US 5206435	A	27-04-1993
WO 9606844	A 07-03-1996	AU 3350995	A	22-03-1996
		BR 9508629	A	25-11-1997
		CA 2198010	A	07-03-1996
		EP 0777669	A	11-06-1997
		FI 970786	A	25-02-1997
		HU 77222	A	02-03-1998
		JP 10505593	T	02-06-1998
		NO 970847	A	25-02-1997
WO 9749410	A 31-12-1997	AU 3262697	A	14-01-1998